Drugs / GT307
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07534813 | Apr 2026 → May 2028 | neoplasm | Grit Biotechnology | Withdrawn | No outcome recorded |
| — | NCT06453057 | Jul 2024 → Jun 2027 expected | — | Grit Biotechnology | Recruiting | No outcome recorded |
| — | NCT06819280 | Jun 2024 → May 2027 expected | — | Grit Biotechnology | Recruiting | No outcome recorded |
| — | NCT06397963 | Apr 2024 → Apr 2027 expected | cancer | Grit Biotechnology | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-24 | Grit Biotechnology | Regulatory 沙砾生物新一代基因敲除型TIL产品GT307注射液获美国FDA IND批准 gritbio.com ↗
2025年12月23日，沙砾生物自主研发的新一代基因敲除型肿瘤浸润淋巴细胞（Tumor-Infiltrating Lymphocytes, TIL）产品 GT307 注射液，获得美国食品药品监督管理局（FDA）新药临床试验（IND）批准。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-24 | Grit Biotechnology | 沙砾生物新一代基因敲除型TIL产品GT307注射液获美国FDA IND批准 gritbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GT307 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06453057 ↗ |
| Modality | Cell therapy | “Autologous Tumor-Infiltrating Lymphocyte (GT307 injection )” NCT06397963 ↗ |